Available technologies
We have technologies available for licensing or further collaborative development.
See the list of technologies below. We also manage a wide range of MRC technologies.
Therapeutic pipeline
Beta amyloid-targeted therapeutic antibody
Modality
BiotherapeuticsTherapeutic area
NeuroscienceAdvantages
A novel approach to specifically target Aβ N-terminal oligomers
Background info
TAPAS specifically recognises the truncated toxic forms pyroglutamate (AβpE3) and Aβ4-42, but not Aβ1-42 showed efficacy in vivo in different models of Alzheimer’s disease.
Indication
Alzheimer’s Disease
Intellectual property
Pending patent applications: WO20070225; Granted patents: EP2847217 B1; EP3269736 B1; US9617332 BB; HK11207869 B
TASK-2 Activators
Modality
Small moleculesTherapeutic area
NeuroscienceAdvantages
Despite important roles in pathophysiology, K2Ps have proven a difficult target class to modulate with small molecules. LifeArc has developed and successfully deployed a novel system to identify small molecule K2P activators, and have strategic relationships in place to deliver high quality drug discovery in the K2P space.
Background info
Two pore domain potassium channels (K2Ps) have been implicated in a number of human diseases including Pain and Migraine. A number of K2Ps show genetic linkage (e.g. Migraine for TASK2 and TRESK). LifeArc has active chemistry programs for TASK-2 with potent and efficacious activators identified.
Indication
Pain and Migraine
Diagnostic pipeline
TB-MBLA
Disease area
InfectionModality
qPCR/ddPCRAdvantages
Faster than current methods; more sensitive and specific than current standard of care
Background info
Culture-free method to accurately estimate viable (active) bacteria targeting a high copy number biomarker
Indication
Tuberculosis – pulmonary TB detection and treatment monitoring assay
Intellectual property
No patents relating to the assay; however, know-how and technical design files to ISO13485